```html

Junctional Tachycardia (AV Nodal Re‑entry Tachycardia) – A Patient‑Friendly Guide

Overview

Junctional tachycardia, also known as AV‑nodal re‑entry tachycardia (AVNRT), is a type of supraventricular arrhythmia in which an electrical circuit forms within or near the atrioventricular (AV) node, causing the heart to beat rapidly—typically 150‑250 beats per minute (bpm). Unlike atrial fibrillation, AVNRT originates from a re‑entrant loop in the conduction system itself, so the atria and ventricles usually contract in a coordinated (1:1) fashion.

AVNRT is the most common paroxysmal supraventricular tachycardia (PSVT); it accounts for about 60‑70% of PSVT cases. The condition can affect anyone, but it is most prevalent in:

• Young adults (20‑40 years old)
• Women (≈55‑60% of diagnosed cases)
• Individuals with a structurally normal heart

Overall prevalence is estimated at 2.25 per 1,000 people worldwide, with higher rates in clinical populations that undergo electrophysiology studies. While most episodes are brief and self‑terminating, some patients experience frequent or sustained episodes that limit daily activities.

Symptoms

Symptoms arise from the sudden increase in heart rate and can vary from mild flutter to severe discomfort. Common manifestations include:

• Palpitations – a rapid, pounding, or “flipping” sensation in the chest.
• Chest discomfort – pressure, tightness, or mild pain; often mistaken for angina.
• Shortness of breath – especially during activity or when an episode starts.
• Dizziness or light‑headedness – due to reduced cardiac output.
• Syncope (fainting) – rare, but can occur if the rate is extremely high or prolonged.
• Fatigue – persistent tiredness after an episode.
• Headache – caused by rapid blood flow changes.
• Blurred vision – transient visual disturbances.
• Anxiety or feeling of panic – the sudden onset can trigger a stress response.
• Neck pulsations – visible “water‑hammer” pulses in the neck, especially in younger patients.

Because AVNRT often begins and ends abruptly, many people attribute the sensation to anxiety or “stress.” However, repeated episodes warrant evaluation.

Causes and Risk Factors

Underlying Mechanism

AVNRT results from a re‑entrant circuit that uses two pathways within the AV node:

• Fast pathway – conducts impulses quickly but has a relatively long refractory period.
• Slow pathway – conducts more slowly but recovers faster.

When a premature atrial beat encounters a still‑refractory fast pathway but a recovered slow pathway, the impulse can travel down the slow route and retro‑grade up the fast route, creating a loop that repeatedly stimulates the atria and ventricles at a rapid rate.

Risk Factors

• Age 20‑40 – the conduction system is more prone to dual‑pathway physiology in this age group.
• Female sex – hormonal influences may affect AV nodal refractoriness.
• Family history of SVT – genetic predisposition to dual‑pathway anatomy.
• Caffeine, nicotine, or alcohol – stimulants lower the threshold for premature atrial beats.
• Medications that provoke ectopy – e.g., decongestants, certain asthma inhalers.
• Underlying structural heart disease – rare, but conditions like Wolff‑Parkinson‑White (WPW) can coexist.
• Hyperthyroidism – excess thyroid hormone increases heart rate and ectopic activity.

Diagnosis

Because AVNRT is paroxysmal (episodes start and stop suddenly), catching it during a medical visit can be challenging. Diagnosis relies on a combination of history, physical examination, and targeted testing.

1. Electrocardiogram (ECG)

• During an episode – a narrow‑complex (QRS < 120 ms) tachycardia at 150‑250 bpm with a regular rhythm. P‑waves are often hidden within or just after the QRS complex (retrograde P‑waves).
• Between episodes – ECG is usually normal.

2. Ambulatory Monitoring

• Holter monitor (24‑48 h) – records rhythm continuously; useful if episodes are frequent.
• Event recorder or patch monitor (up to 30 days) – patient activates the device when symptoms begin.

3. Electrophysiology Study (EPS)

Considered the gold‑standard when non‑invasive tests are inconclusive or when a catheter‑ablation is being planned. During EPS, catheters placed in the heart record intracardiac signals and can deliberately induce the tachycardia, confirming AVNRT and identifying the exact pathways.

4. Additional Tests (rule‑out causes)

• Thyroid function tests (to exclude hyperthyroidism)
• Blood work for electrolyte abnormalities
• Echocardiogram (to evaluate structural heart disease)

Treatment Options

Treatment aims to terminate acute episodes, prevent recurrences, and improve quality of life. Choice depends on episode frequency, severity, patient age, comorbidities, and personal preference.

1. Acute Termination

• Vagal maneuvers – bearing down (Valsalva), coughing, or facial immersion in cold water; increase parasympathetic tone and can break the re‑entry circuit.
• Medication
  • IV Adenosine – rapid 6‑mg bolus (may repeat 12 mg); the most effective first‑line drug for terminating AVNRT.
  • Beta‑blockers (e.g., metoprolol) or non‑dihydropyridine calcium‑channel blockers (e.g., verapamil) – can be given orally if adenosine is contraindicated.
• Electrical cardioversion – synchronized shock (50‑100 J) if the patient is hemodynamically unstable or if drug therapy fails.

2. Long‑Term Prevention

• Beta‑blockers (metoprolol, atenolol) – reduce AV nodal conduction speed, lowering recurrence risk.
• Calcium‑channel blockers (diltiazem, verapamil) – useful for patients who cannot tolerate beta‑blockers.
• Anti‑arrhythmic drugs (flecainide, propafenone, or sotalol) – reserved for refractory cases due to side‑effect profile.
• Catheter Ablation – radiofrequency or cryo‑ablation targeting the slow pathway. Success rates >95% with <1% major complication risk, making it the preferred definitive therapy for symptomatic patients.

3. Lifestyle Modifications

• Limit caffeine, nicotine, and alcohol.
• Maintain adequate hydration; dehydration can precipitate ectopic beats.
• Manage stress through relaxation techniques (deep breathing, yoga, meditation).
• Regular aerobic exercise – improves autonomic balance, but avoid extreme exertion until rate control is achieved.

Living with Junctional Tachycardia (AV Nodal Re‑entry Tachycardia)

Even with treatment, many patients need day‑to‑day strategies to keep episodes at bay.

• Track your episodes – use a diary or mobile app to note triggers, duration, and response to maneuvers.
• Carry a rescue medication card – list name/dosage of adenosine (if prescribed) or a beta‑blocker you may need to take.
• Know how to perform vagal maneuvers – practice the Valsalva technique at home.
• Stay up‑to‑date with follow‑up – regular visits allow medication titration and early detection of complications.
• Educate close contacts – family, coworkers, and teachers should know what to do if you become symptomatic (e.g., sitting you down, calling emergency services).

Prevention

While you cannot change intrinsic AV nodal anatomy, you can lower the likelihood of episodes:

• Limit intake of stimulants (≥300 mg caffeine/day, >2 drinks of alcohol, tobacco).
• Control thyroid disease and correct electrolyte imbalances.
• Manage comorbid conditions such as hypertension and sleep apnea.
• Practice regular moderate‑intensity exercise (150 min/week) to improve autonomic tone.
• Avoid over‑the‑counter decongestants containing pseudoephedrine or phenylephrine without physician guidance.

Complications

When left untreated or poorly controlled, AVNRT can lead to:

• Heart failure – sustained tachycardia may cause tachy‑cardiomyopathy.
• Syncope or injury – due to sudden loss of consciousness.
• Ischemic chest pain – especially in patients with underlying coronary artery disease.
• Psychological distress – anxiety or depression secondary to unpredictable episodes.
• Medication side effects – bradycardia, hypotension, or pro‑arrhythmic effects from anti‑arrhythmics.

When to Seek Emergency Care

References

1. Mayo Clinic. Supraventricular tachycardia (SVT). Accessed May 2024.
2. American Heart Association. AV Nodal Re‑entry Tachycardia. 2023.
3. Cleveland Clinic. AV Nodal Re‑entry Tachycardia (AVNRT). 2022.
4. National Institutes of Health, National Heart, Lung, and Blood Institute. AV Nodal Re‑entry Tachycardia. 2021.
5. WHO. Cardiovascular diseases. 2023.
6. Zipes, D.P., et al. *Mechanisms of Arrhythmias*. 2nd ed. Elsevier, 2022.

```